Foundation Medicine, Inc., a Boston, MA-based personalized cancer medicine company that aims to bring comprehensive cancer genome analysis into routine clinical care, has completed a $25m Series A financing.
The round was led by Third Rock Ventures.
The capital infusion will be used to develop clinical laboratory tests – using innovative sequencing and other advanced technologies – that will analyze the relevant tumor genomic and other molecular information in individual patients’ cancers and connect it with a knowledge base of clinical data to help oncologists personalize treatment.
Foundation Medicine’s founding scientific advisors are recognized leaders in the field of cancer genomics and its translation into clinical practice. Biotech industry veteran Alexis Borisy is serving as the founding chief executive officer of the company.